These combined observations suggest that MAGE-C1/CT7 gene might plays a role in cell cycle in MM and that silencing of MAGE-C1/CT7 enhances the anti-myeloma effect of bortezomib. The gene discussed is MAGEC1; the disease is plasma cell myeloma.